No Data
YZYBIO-B (02496): Hu Liaoyuan has been appointed as Chief Scientific Officer.
YZYBIO-B (02496) announced that Hu Liaoyuan has been appointed as the Chief Scientific Officer of the company. Hu Liaoyuan will be responsible for...
YZYBIO-B: 2024 ANNUAL REPORT
YZYBIO-B: ANNUAL RESULTS ANNOUNCEMENTFOR THE YEAR ENDED DECEMBER 31, 2024
YZYBIO-B (02496.HK) expects its annual loss to decrease by at least 35%.
On March 24, Gelonghui reported that YZYBIO-B (02496.HK) announced that the group expects the consolidated loss for the fiscal year ending December 31, 2024, to decrease by at least 35% compared to the consolidated loss of RMB 191.7 million for the fiscal year ending December 31, 2023. The Board of Directors believes that the reduction in consolidated loss is primarily due to (i) the Trade under the licensing and cooperation agreement signed with Chengdu Tianqing Pharmaceutical Holdings Co., Ltd. on October 7, 2024; and (ii) incurred listing expenses of approximately RMB 24.6 million in 2023 (2024.
YZYBIO-B: INSIDE INFORMATION -PROFIT ALERT - EXPECTED REDUCTION IN LOSS
YZYBIO-B (02496.HK) plans to hold a Board of Directors meeting on March 28 to approve the annual performance.
Gelonghui reported on March 18 that YZYBIO-B (02496.HK) announced that the Board of Directors has scheduled a board meeting on March 28, 2025 (Friday) to consider and approve the annual results and its release for the year ending December 31, 2024, as well as to address other matters.
